Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US
24 juin 2024 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
12 juin 2024 05h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs
12 juin 2023 09h00 HE
|
Helsinn Healthcare S.A.
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
03 févr. 2023 08h00 HE
|
Helsinn
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 - Helsinn Group (“Helsinn”), a fully integrated...
Helsinn closes financing agreement with Oberland Capital
10 janv. 2023 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisitionDr...
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
09 janv. 2023 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn Group...
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
29 nov. 2022 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region
28 nov. 2022 06h00 HE
|
Helsinn Healthcare S.A.
Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer
19 mai 2022 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of...
Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico
16 févr. 2022 07h00 HE
|
Helsinn Healthcare S.A.
Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Toronto, Ontario and Lugano, Switzerland, February 16, 2022 ...